Pradaxa Lawsuit News: Bernstein Liebhard LLP Notes Issuance of Pretrial Schedule for First Federal Pradaxa Trial
The Firm is evaluating Pradaxa lawsuits on behalf of patients who allegedly suffered episodes of uncontrollable internal bleeding due to their use of Pradaxa.
New York, NY (PRWEB) April 27, 2014
Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/ ) filed on behalf of individuals who allegedly suffered uncontrollable internal bleeding allegedly due to the blood thinner continue to move forward in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to an Order issued on April 9, 2014, the Court has established a pretrial schedule for the proceeding’s first bellwether trial. Jury selection for the first Pradaxa trial is scheduled to begin on September 8, 2014. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
“Bellwether trials often provide valuable insight into how juries will rule in similar cases. Our Firm has heard from numerous individuals who were allegedly harmed by Pradaxa bleeding side effects, and will continue to monitor this litigation closely,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free and confidential case evaluations to individuals who allegedly experienced cerebral hemorrhage, gastrointestinal bleeding, or other episodes of serious internal bleeding due to Pradaxa.
Pradaxa Bleeding Allegations
Court documents indicate that more than 2,500 Pradaxa lawsuits have been filed in the litigation underway in the Southern District of Illinois. The complaints allege that Boehringer Ingelheim failed to provide warnings regarding the lack of a reversal agent for the internal bleeding that can sometimes occur with Pradaxa. Plaintiffs also claim that the company wrongly touted Pradaxa as an improvement to warfarin, a blood thinner that has been used for decades. They point out that while warfarin bleeding can be stopped via the administration of vitamin K, there is no readily available antidote to Pradaxa bleeding.
Boehringer Ingelheim brought Pradaxa to the U.S. market in October 2010, after the U.S. Food & Drug Administration (FDA) approved its use to decrease the risk of strokes in people who suffer from atrial fibrillation. On April 7, 2014, the company announced that the FDA had expanded the approved uses of Pradaxa to include the treatment of venous thromboembolism, including both deep venous thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE in patients who have been previously treated.*
In February, a report aired by 7 Action News in Detroit asserted that Pradaxa may be the most complained about drug in the U.S. According to the broadcast, the FDA has received reports of 12,494 injuries and 1,158 deaths among Pradaxa users since the blood thinner was launched in the U.S. Many of these cases detailed episodes of uncontrollable internal bleeding. **
Individuals who allegedly suffered Pradaxa bleeding side effects may be entitled to compensation from Boehringer Ingelheim. Find out more about Pradaxa lawsuits at Bernstein Liebhard LLP’s website. Please call 800-511-5092 to schedule a free, no obligation case review.
*us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/04-07-14-fda-approves-pradaxa-dabigatran-etexilate-mesylate-treatment-reduction-risk-of-recurrence-deep-venous-thrombosis-pulmonary-embolism.html, Boehringer Ingelheim, April 7, 2014
**wxyz.com/money/consumer/pradaxa-lawsuit, 7 Action News, February 25, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
For the original version on PRWeb visit: http://www.prweb.com/releases/pradaxa-lawsuit/pradaxa-bleeding/prweb11798656.htm